Renin Angiotensin System Blocker Fetopathy: A Midwest Pediatric Nephrology Consortium Report

Journal of Pediatrics

Volumn 167, Issue 4, 2015, Pages 881-885

  Nadeem, Shahid ^a   Hashmat, Shireen ^b   Defreitas, Marissa J ^c   Westreich, Katherine D ^d   Shatat, Ibrahim F ^e   Selewski, David T ^f   Onder, Ali M ^g   Chiang, Myra ^g   Weaver, Donald J ^h   Steinke, Julia ⁱ   Barcia, John ^j   Hernandez, Joel ^k   Hidalgo, Guillermo ^l   Ingraham, Susan E ^m   Abitbol, Carolyn L ^c   Pan, Cynthia ^b   Greenbaum, Larry A ^n,o  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^f UNIVERSITY OF MICHIGAN   (United States)

^g WEST VIRGINIA UNIVERSITY   (United States)

^h Levine Children s Hospital   (United States)

ⁱ HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

^k SEATTLE CHILDREN S HOSPITAL   (United States)

^l EAST CAROLINA UNIVERSITY   (United States)

^m NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁿ EMORY UNIVERSITY   (United States)

^o CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; MOEXIPRIL; OLMESARTAN; RAMIPRIL; VALSARTAN;

ACUTE KIDNEY FAILURE; ADOLESCENT; ARACHNOID CYST; ARTICLE; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL BLINDNESS; CEREBRAL PALSY; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMPLICATION; CYCSTIC ENCEPHALOMALACIA; DIALYSIS; ENCEPHALOMALACIA; FEMALE; FETUS; FETUS DISEASE; FETUS RISK; FIRST TRIMESTER PREGNANCY; HEART ATRIUM SEPTUM DEFECT; HUMAN; HYPOCALVARIA; INFANT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LUNG HYPOPLASIA; MICROCEPHALY; MORBIDITY; OLIGOHYDRAMNIOS; PATENT DUCTUS ARTERIOSUS; PERCEPTION DEAFNESS; PNEUMOMEDIASTINUM; PNEUMOTHORAX; PREGNANCY; PRENATAL CARE; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SKULL DEFECT; CLINICAL TRIAL; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; FOLLOW UP; MALE; MULTICENTER STUDY; NEPHROLOGY; NEWBORN; PROCEDURES; RENAL REPLACEMENT THERAPY; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; UNITED STATES;

ADOLESCENT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHILD; CHILD, PRESCHOOL; FEMALE; FETUS; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; MALE; MATERNAL EXPOSURE; MIDWESTERN UNITED STATES; NEPHROLOGY; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 84952881850     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2015.05.045     Document Type: Article

References (23)

1. 1 Pryde, P.G., Sedman, A.B., Nugent, C.E., Barr, M. Jr., Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 3 (1993), 1575–1582.
2. 2 Tylicki, L., Lizakowski, S., Rutkowski, B., Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions. J Nephrol 25 (2012), 900–910.
3. 3 Guron, G., Friberg, P., An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 18 (2000), 123–137.
4. 4 Chen, Y., Lasaitiene, D., Gabrielsson, B.G., Carlsson, L.M., Billig, H., Carlsson, B., et al. Neonatal losartan treatment suppresses renal expression of molecules involved in cell-cell and cell-matrix interactions. J Am Soc Nephrol 15 (2004), 1232–1243.
5. 5 Cooper, W.O., Hernandez-Diaz, S., Arbogast, P.G., Dudley, J.A., Dyer, S., Gideon, P.S., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354 (2006), 2443–2451.
6. 6 Ratnapalan, S., Koren, G., Taking ACE inhibitors during pregnancy. Is it safe?. Can Fam Physician 48 (2002), 1047–1049.
7. 7 Friberg, P., Sundelin, B., Bohman, S.O., Bobik, A., Nilsson, H., Wickman, A., et al. Renin-angiotensin system in neonatal rats: induction of a renal abnormality in response to ACE inhibition or angiotensin II antagonism. Kidney Int 45 (1994), 485–492.
8. 8 Shotan, A., Widerhorn, J., Hurst, A., Elkayam, U., Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96 (1994), 451–456.
9. 9 Schaefer, C., Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 67 (2003), 591–594.
10. 10 Oppermann, M., Padberg, S., Kayser, A., Weber-Schoendorfer, C., Schaefer, C., Angiotensin-II receptor 1 antagonist fetopathy—risk assessment, critical time period and vena cava thrombosis as a possible new feature. Br J Clin Pharmacol 75 (2013), 822–830.
11. 11 Bullo, M., Tschumi, S., Bucher, B.S., Bianchetti, M.G., Simonetti, G.D., Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 60 (2012), 444–450.
12. 12 Miura, K., Sekine, T., Iida, A., Takahashi, K., Igarashi, T., Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker. Pediatr Nephrol 24 (2009), 1235–1238.
13. 13 Bowen, M.E., Ray, W.A., Arbogast, P.G., Ding, H., Cooper, W.O., Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. Am J Obstet Gynecol 198 (2008), 291–295.
14. 14 Karthikeyan, V.J., Ferner, R.E., Baghdadi, S., Lane, D.A., Lip, G.Y., Beevers, D.G., Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens 29 (2011), 396–399.
15. 15 Schwartz, G.J., Munoz, A., Schneider, M.F., Mak, R.H., Kaskel, F., Warady, B.A., et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20 (2009), 629–637.
16. 16 Sedman, A.B., Kershaw, D.B., Bunchman, T.E., Recognition and management of angiotensin converting enzyme inhibitor fetopathy. Pediatr Nephrol 9 (1995), 382–385.
17. 17 Sekine, T., Miura, K., Takahashi, K., Igarashi, T., Children's toxicology from bench to bed–Drug-induced renal injury (1): the toxic effects of ARB/ACEI on fetal kidney development. J Toxicol Sci 34:Suppl 2 (2009), SP245–SP250.
18. 18 Filler, G., Wong, H., Condello, A.S., Charbonneau, C., Sinclair, B., Kovesi, T., et al. Early dialysis in a neonate with intrauterine lisinopril exposure. Arch Dis Child 88 (2003), F154–F156.
19. 19 Hanssens, M., Keirse, M.J., Vankelecom, F., Van Assche, F.A., Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 78 (1991), 128–135.
20. 20 Wolf, G., Ritz, E., Combination therapy with ACE inhibitors and angotensin II receptor blockers to halt progression of chronic kidney disease: Pathophysiology and indications. Kidney Int 67 (2005), 799–812.
21. 21 Mills, J.L., Malformations in infants of diabetic mothers. Birth Defects Res A Clin Mol Teratol 88 (2010), 769–778.
22. 22 Krause, T., Lovibond, K., Caulfield, M., McCormack, T., Williams, B., Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ, 343, 2011, d4891.
23. 23 Nadeem, S., Batisky, D.L., Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases. Pediatr Nephrol 29 (2014), 2105–2111.